

## 1. Company details

Name of entity:	Novogen Limited
ABN:	37 063 259 754
Reporting period:	For the year ended 30 June 2014
Previous period:	For the year ended 30 June 2013

## 2. Results for announcement to the market

			\$
Revenues from ordinary activities	down	92.2% to	86,686
Loss from ordinary activities after tax attributable to the owners of Novogen Limited	up	624.4% to	(7,467,319)
Loss for the year attributable to the owners of Novogen Limited	up	624.4% to	(7,467,319)

### Dividends

There were no dividends paid, recommended or declared during the current financial period.

### Comments

The loss for the consolidated entity after providing for income tax and non-controlling interest amounted to \$7,467,319 (30 June 2013: \$1,030,852).

Refer to the attached Directors' report and financial statements for further analysis information.

## 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	(0.33)	1.09

## 4. Control gained over entities

On 7 November 2013, the company acquired 85% interest in CanTx. Inc.

## 5. Loss of control over entities

Not applicable.

## 6. Dividends

### Current period

There were no dividends paid, recommended or declared during the current financial period.

### Previous period

On 27 November 2012, a dividend of \$24,774,709 was paid via an in-specie distribution of shares in MEI Pharma, Inc. representing 23.87 cents per ordinary share.

## 7. Dividend reinvestment plans

Not applicable.

---

## 8. Details of associates and joint venture entities

Not applicable.

---

## 9. Foreign entities

*Details of origin of accounting standards used in compiling the report:*

Not applicable.

---

## 10. Audit qualification or review

*Details of audit/review dispute or qualification (if any):*

The financial statements have been audited and an unqualified opinion is attached as part of the Directors' report and financial statements.

---

## 11. Attachments

*Details of attachments (if any):*

The Directors' report and financial statements of Novogen Limited for the year ended 30 June 2014 is attached.

---

## 12. Signed



Signed \_\_\_\_\_

Date: 28 August 2014

Graham Kelly  
Chairman  
Sydney